Table 1.
Representative clinical trials of chemoimmunotherapy.
| Chemotherapeutic Agents | Immunotherapeutic Agents | Cancer Type | Phase | Identifier |
|---|---|---|---|---|
| Cisplatin (CP) + docetaxel (DTX) | Dendritic cells | Head and neck cancer | I | NCT01149902 |
| Irinotecan + temozolomide | GM-CSF | Neuroblastoma | I | NCT03189706 |
| CP | Pembrolizumab | Ovarian cancer recurrent | I/II | NCT03734692 |
| Fulvestrant + DTX | Trastuzumab, pertuzumab | HER2-positive breast cancer, ER-positive breast cancer | I/II | NCT02345772 |
| CP, doxorubicin (DOX), etoposide | Epratuzumab | Recurrent childhood acute lymphoblastic leukemia | I/II | NCT00098839 |
| Carboplatin, DOX | Tocilizumab + IFN-α-2b | Recurrent ovarian cancer | I/II | NCT01637532 |
| DTX | Cemiplimab | Prostate cancer metastatic | II | NCT03951831 |
| Carboplatin + etoposide + lamivudine | Atezolizumab | Extensive-stage lung small cell carcinoma | II | NCT04696575 |
| CHOP (CP + DOX + vincristine + prednisone) | Alemtuzumab | Lymphoma, T cell, peripheral | II | NCT01679860 |
| CHOP | Rituximab | Lymphoma, large B cell | II | NCT03536039 |
| Carboplatin | GM-CSF, rIFN-γ | Ovarian cancer, fallopian tube cancer, peritoneal cancer | II | NCT00501644 |
| Cisplatin, carboplatin, etoposide | Durvalumab, ceralasertib | Extensive-stage small cell lung cancer | II | NCT04699838 |
| Cisplatin + gemcitabine | Atezolizumab | Bladder cancer | II | NCT04630730 |
| Bendamustine + mitoxantrone | Rituximab | Follicular lymphoma | II | NCT01523860 |
| Pemetrexed + carboplatin |
Durvalumab | Non-small cell lung cancer, metastatic | II | NCT04163432 |
| Bendamustine | Obinutuzumab | Mantle cell lymphoma, non-Hodgkin lymphoma | II | NCT03311126 |
| Fludarabine + CP | Ofatumumab | B-cell lymphoid leukemia | II | NCT01762202 |
| Cabazitaxel + carboplatin | Nivolumab + ipilimumab | Metastatic prostate neuroendocrine carcinoma, metastatic prostate cancer | II | NCT04709276 |
| Fludarabine + CP | Ofatumumab | Small lymphocytic Lymphoma, chronic lymphocytic leukemia | II | NCT01145209 |
| 5-Fluorouracil | IFN | Colon cancer stage III | III | NCT00309530 |
| Fludarabine + CP | Rituximab | Chronic lymphocytic leukemia | III | NCT03836261 |
| DHAP (dexamethasone + cytarabine + CP) | Ofatumumab, rituximab | Relapsed or refractory diffuse large B cell lymphoma | III | NCT01014208 |
| Venetoclax, ibrutinib | Rituximab, obinutuzumab | Chronic lymphocytic leukemia | III | NCT02950051 |
| Carboplatin + paclitaxel | Nivolumab | Non-small cell lung cancer | III | NCT04564157 |